The prevalence of monogenic diabetes in Australia: the Fremantle Diabetes Study Phase II

2017 ◽  
Vol 207 (8) ◽  
pp. 344-347 ◽  
Author(s):  
Timothy ME Davis ◽  
Ashley E Makepeace ◽  
Sian Ellard ◽  
Kevin Colclough ◽  
Kirsten Peters ◽  
...  
Keyword(s):  
Phase Ii ◽  
Monogenic Diabetes ◽  
Study Phase

Open Scenario Study, Phase II Report: Assessment and Development of Approaches for Satisfying Unclassified Scenario Needs

2010 ◽  
Author(s):  
Jason A. Dechant ◽  
James S. Thomason ◽  
Ylli Bajraktari ◽  
Mary C. Flythe ◽  
Anthony C. Hermes ◽  
...  
Keyword(s):  
Phase Ii ◽  
Study Phase ◽  
Scenario Study

Condensing Heat Exchanger Microbial Growth and Control Study-Phase II

1993 ◽  
Author(s):  
Robert W. Marsh ◽  
Mark E. Caron ◽  
Carol Metselaar ◽  
John Steele
Keyword(s):  
Heat Exchanger ◽  
Phase Ii ◽  
Microbial Growth ◽  
Study Phase ◽  
Condensing Heat Exchanger ◽  
And Control ◽  
Control Study

scholarly journals Influence of Renin-Angiotensin System Inhibitors on Lower Respiratory Tract Infections in Type 2 Diabetes: The Fremantle Diabetes Study Phase II

2020 ◽  
Author(s):  
Timothy M E Davis ◽  
Wendy A Davis
Keyword(s):  
Type 2 Diabetes ◽  
Respiratory Tract ◽  
Phase Ii ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Study Phase ◽  
Lower Respiratory Tract Infections ◽  
Tract Infections

Objective:<b> </b>To determine whether<b> </b>angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) protect against lower respiratory tract infections complicating type 2 diabetes. <p>Research design and methods:<b> </b>Of 1,732 participants with diabetes recruited to the longitudinal observational Fremantle Diabetes Study Phase II (FDS2) between 2008 and 2011, 1,482 had confirmed type 2 diabetes (mean age of 65.8 years, 51.6% were males, median diabetes duration 9.0 years). All were followed for hospitalizations for/with, or deaths from, pneumonia/influenza ascertained from validated administrative data linkage from study entry to end-2016. Cox and competing risk regression were used to identify independent predictors of this outcome.</p> <p>Results:<b> </b>Two-thirds of participants (n=982) were taking an ACEi and/or ARB at study entry (498 (33.6%) ACEi, 408 (27.5%) ARB, 76 (5.1%) both).<b> </b>During 9,511 person-years of follow-up (mean 6.4±2.0 years), 174 participants had incident pneumonia/influenza (156 hospitalizations, 18 deaths without hospitalization). In Cox regression analysis, baseline ACEi/ARB use was independently associated with a reduced risk of incident pneumonia/influenza (cause-specific hazard ratio (HR) (95% confidence interval) 0.64 (0.45, 0.89), <i>P</i>=0.008). Allowing for the competing risk of death did not change this finding (subdistribution HR 0.67 (0.48, 0.95), <i>P</i>=0.024), and similar reductions were seen for ACEi, ARB alone, and ACEi/ARB combination therapy. There was no significant change in use of ACEi/ARB during follow-up (interaction with ln(time), <i>P</i>=0.70). Other significant predictors of incident pneumonia/influenza were previously reported, clinically plausible variables.</p> <p>Conclusions:<b> </b>ACEi/ARB reduce the risk of pneumonia/influenza in community-based people with type 2 diabetes.<b><br> </b></p>

scholarly journals Influence of Renin-Angiotensin System Inhibitors on Lower Respiratory Tract Infections in Type 2 Diabetes: The Fremantle Diabetes Study Phase II

2020 ◽  
Author(s):  
Timothy M E Davis ◽  
Wendy A Davis
Keyword(s):  
Type 2 Diabetes ◽  
Respiratory Tract ◽  
Phase Ii ◽  
Lower Respiratory Tract ◽  
Respiratory Tract Infections ◽  
Study Phase ◽  
Lower Respiratory Tract Infections ◽  
Tract Infections

Objective:<b> </b>To determine whether<b> </b>angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) protect against lower respiratory tract infections complicating type 2 diabetes. <p>Research design and methods:<b> </b>Of 1,732 participants with diabetes recruited to the longitudinal observational Fremantle Diabetes Study Phase II (FDS2) between 2008 and 2011, 1,482 had confirmed type 2 diabetes (mean age of 65.8 years, 51.6% were males, median diabetes duration 9.0 years). All were followed for hospitalizations for/with, or deaths from, pneumonia/influenza ascertained from validated administrative data linkage from study entry to end-2016. Cox and competing risk regression were used to identify independent predictors of this outcome.</p> <p>Results:<b> </b>Two-thirds of participants (n=982) were taking an ACEi and/or ARB at study entry (498 (33.6%) ACEi, 408 (27.5%) ARB, 76 (5.1%) both).<b> </b>During 9,511 person-years of follow-up (mean 6.4±2.0 years), 174 participants had incident pneumonia/influenza (156 hospitalizations, 18 deaths without hospitalization). In Cox regression analysis, baseline ACEi/ARB use was independently associated with a reduced risk of incident pneumonia/influenza (cause-specific hazard ratio (HR) (95% confidence interval) 0.64 (0.45, 0.89), <i>P</i>=0.008). Allowing for the competing risk of death did not change this finding (subdistribution HR 0.67 (0.48, 0.95), <i>P</i>=0.024), and similar reductions were seen for ACEi, ARB alone, and ACEi/ARB combination therapy. There was no significant change in use of ACEi/ARB during follow-up (interaction with ln(time), <i>P</i>=0.70). Other significant predictors of incident pneumonia/influenza were previously reported, clinically plausible variables.</p> <p>Conclusions:<b> </b>ACEi/ARB reduce the risk of pneumonia/influenza in community-based people with type 2 diabetes.<b><br> </b></p>

Complementary medicine use in community-based Australians with type 2 diabetes: The Fremantle Diabetes Study Phase II (FDS2)

2018 ◽  
Vol 14 (8) ◽  
pp. e39-e40
Author(s):  
Rhonda M. Clifford ◽  
Tatiana Yarash ◽  
Farhat Fatima ◽  
Imrana Sharif ◽  
Timothy M.E. Davis ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Complementary Medicine ◽  
Phase Ii ◽  
Study Phase ◽  
Medicine Use ◽  
Community Based

Advanced Gun Fire Control System (AGFCS) Design Study (Phase II). Volume I.

1977 ◽  
Author(s):  
Robert L. Berg ◽  
William J. Murphy ◽  
Dennis E. Simmons
Keyword(s):  
Control System ◽  
Phase Ii ◽  
Study Phase ◽  
Fire Control ◽  
Design Study

Risk factors and outcomes of anxiety symptom trajectories in type 2 diabetes: the Fremantle Diabetes Study Phase II

2020 ◽  
Author(s):  
S. R. Whitworth ◽  
D. G. Bruce ◽  
S. E. Starkstein ◽  
T. M. E. Davis ◽  
T. C. Skinner ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Phase Ii ◽  
Anxiety Symptom ◽  
Study Phase ◽  
Symptom Trajectories
Sign in / Sign up

Export Citation Format

Share Document